1010 related articles for article (PubMed ID: 28339459)
21. Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.
de la Hoya M; Soukarieh O; López-Perolio I; Vega A; Walker LC; van Ierland Y; Baralle D; Santamariña M; Lattimore V; Wijnen J; Whiley P; Blanco A; Raponi M; Hauke J; Wappenschmidt B; Becker A; Hansen TV; Behar R; Investigators K; Niederacher D; Arnold N; Dworniczak B; Steinemann D; Faust U; Rubinstein W; Hulick PJ; Houdayer C; Caputo SM; Castera L; Pesaran T; Chao E; Brewer C; Southey MC; van Asperen CJ; Singer CF; Sullivan J; Poplawski N; Mai P; Peto J; Johnson N; Burwinkel B; Surowy H; Bojesen SE; Flyger H; Lindblom A; Margolin S; Chang-Claude J; Rudolph A; Radice P; Galastri L; Olson JE; Hallberg E; Giles GG; Milne RL; Andrulis IL; Glendon G; Hall P; Czene K; Blows F; Shah M; Wang Q; Dennis J; Michailidou K; McGuffog L; Bolla MK; Antoniou AC; Easton DF; Couch FJ; Tavtigian S; Vreeswijk MP; Parsons M; Meeks HD; Martins A; Goldgar DE; Spurdle AB
Hum Mol Genet; 2016 Jun; 25(11):2256-2268. PubMed ID: 27008870
[TBL] [Abstract][Full Text] [Related]
22. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
Tesoriero AA; Wong EM; Jenkins MA; Hopper JL; Brown MA; Chenevix-Trench G; Spurdle AB; Southey MC;
Hum Mutat; 2005 Nov; 26(5):495. PubMed ID: 16211554
[TBL] [Abstract][Full Text] [Related]
24.
Bueno-Martínez E; Sanoguera-Miralles L; Valenzuela-Palomo A; Lorca V; Gómez-Sanz A; Carvalho S; Allen J; Infante M; Pérez-Segura P; Lázaro C; Easton DF; Devilee P; Vreeswijk MPG; de la Hoya M; Velasco EA
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200360
[No Abstract] [Full Text] [Related]
25. Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants.
Bueno-Martínez E; Sanoguera-Miralles L; Valenzuela-Palomo A; Esteban-Sánchez A; Lorca V; Llinares-Burguet I; Allen J; García-Álvarez A; Pérez-Segura P; Durán M; Easton DF; Devilee P; Vreeswijk MP; de la Hoya M; Velasco-Sampedro EA
J Pathol; 2022 Sep; 258(1):83-101. PubMed ID: 35716007
[TBL] [Abstract][Full Text] [Related]
26. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
27. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
29. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
[TBL] [Abstract][Full Text] [Related]
30. Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
Montalban G; Fraile-Bethencourt E; López-Perolio I; Pérez-Segura P; Infante M; Durán M; Alonso-Cerezo MC; López-Fernández A; Diez O; de la Hoya M; Velasco EA; Gutiérrez-Enríquez S
Hum Mutat; 2018 Sep; 39(9):1155-1160. PubMed ID: 29969168
[TBL] [Abstract][Full Text] [Related]
31. Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling.
Pensabene M; Spagnoletti I; Capuano I; Condello C; Pepe S; Contegiacomo A; Lombardi G; Bevilacqua G; Caligo MA
Ann Oncol; 2009 May; 20(5):874-8. PubMed ID: 19179552
[TBL] [Abstract][Full Text] [Related]
32. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
[TBL] [Abstract][Full Text] [Related]
33. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
34. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L
Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930
[TBL] [Abstract][Full Text] [Related]
35. Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.
Nix P; Mundt E; Coffee B; Goossen E; Warf BM; Brown K; Bowles K; Roa B
Fam Cancer; 2022 Jan; 21(1):7-19. PubMed ID: 33469799
[TBL] [Abstract][Full Text] [Related]
36. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
[TBL] [Abstract][Full Text] [Related]
38. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
[TBL] [Abstract][Full Text] [Related]
39. Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts.
Whiley PJ; Pettigrew CA; Brewster BL; Walker LC; ; Spurdle AB; Brown MA
BMC Med Genet; 2010 May; 11():80. PubMed ID: 20507642
[TBL] [Abstract][Full Text] [Related]
40. Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2.
Mesman RLS; Calléja FMGR; de la Hoya M; Devilee P; van Asperen CJ; Vrieling H; Vreeswijk MPG
Genet Med; 2020 Aug; 22(8):1355-1365. PubMed ID: 32398771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
